The Neuroimmune Pharmacology of SARS-CoV-2

Santosh Kumar; Sowmya Yelamanchili; Pankaj Seth; Jean M Bidlack; Gurudutt Pendyala; Sanjay Maggirwar; Sulie L Chang

doi:10.1007/s11481-021-10038-z

The Neuroimmune Pharmacology of SARS-CoV-2

J Neuroimmune Pharmacol. 2021 Dec;16(4):699-705. doi: 10.1007/s11481-021-10038-z. Epub 2021 Dec 22.

Authors

Santosh Kumar¹, Sowmya Yelamanchili², Pankaj Seth³, Jean M Bidlack⁴, Gurudutt Pendyala², Sanjay Maggirwar⁵, Sulie L Chang⁶

Affiliations

¹ Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, USA. ksantosh@uthsc.edu.
² Department of Anesthesiology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
³ Cellular and Molecular Neuroscience, National Brain Research Center, Panesar, Haryana, India.
⁴ Department of Pharmacology and Physiology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, USA.
⁵ Department of Microbiology, Immunology & Tropical Medicine, George Washington University School of Medicine and Health Sciences, Washington D.C., USA.
⁶ Institute of Neuroimmune Pharmacology and Department of Biological Sciences, Seton Hall University, South Orange, NJ, USA. sulie.chang@shu.edu.

Abstract

This guest commentary introduces "The Neuroimmune Pharmacology of SARS-CoV-2," a special theme issue for The Journal of Neuroimmune Pharmacology led by the Society on NeuroImmune Pharmacology. The issue builds on the Society's Virtual Workshop on COVID-19 held April 9, 2021. Top row from left: Drs. Santosh Kumar, Sowmya Yelamanchili, Pankaj Seth, Jean M. Bidlack; Bottom row from left: Drs. Gurudutt Pendyala, Sanjay Maggirwar, and Sulie L. Chang.

Keywords: COVID-19; Diversity; Early-career investigators; Equity and inclusion; Neuroimmune pharmacology; Oral history; SARS-CoV-2; Therapeutics; Vaccines; Well-being.

The Neuroimmune Pharmacology of SARS-CoV-2

Authors

Affiliations

Abstract

Publication types

MeSH terms

Grants and funding